Why the FDA's Drug Competition Action Plan Is Bad News for Generic Pharmaceutical Stocks

Zhiyuan Sun, The Motley Fool
Why the FDA's Drug Competition Action Plan Is Bad News for Generic Pharmaceutical Stocks

Here's why a new initiative by the FDA to reduce drug prices is great for patients but should raise the alarm among pharmaceutical investors.